Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.21
CRL's Cash to Debt is ranked lower than
86% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.74 vs. CRL: 0.21 )
Ranked among companies with meaningful Cash to Debt only.
CRL' s 10-Year Cash to Debt Range
Min: 0.05  Med: 0.33 Max: N/A
Current: 0.21
Equity to Asset 0.36
CRL's Equity to Asset is ranked lower than
79% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. CRL: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
CRL' s 10-Year Equity to Asset Range
Min: -0.28  Med: 0.51 Max: 0.72
Current: 0.36
-0.28
0.72
Interest Coverage 14.87
CRL's Interest Coverage is ranked lower than
75% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. CRL: 14.87 )
Ranked among companies with meaningful Interest Coverage only.
CRL' s 10-Year Interest Coverage Range
Min: 1.6  Med: 7.82 Max: 83.91
Current: 14.87
1.6
83.91
F-Score: 7
Z-Score: 2.86
M-Score: -2.41
WACC vs ROIC
8.26%
11.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.72
CRL's Operating margin (%) is ranked higher than
84% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. CRL: 13.72 )
Ranked among companies with meaningful Operating margin (%) only.
CRL' s 10-Year Operating margin (%) Range
Min: -33.48  Med: 18.27 Max: 22.58
Current: 13.72
-33.48
22.58
Net-margin (%) 9.56
CRL's Net-margin (%) is ranked higher than
84% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.51 vs. CRL: 9.56 )
Ranked among companies with meaningful Net-margin (%) only.
CRL' s 10-Year Net-margin (%) Range
Min: -38.84  Med: 9.04 Max: 14.3
Current: 9.56
-38.84
14.3
ROE (%) 18.68
CRL's ROE (%) is ranked higher than
86% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. CRL: 18.68 )
Ranked among companies with meaningful ROE (%) only.
CRL' s 10-Year ROE (%) Range
Min: -230.9  Med: 12.39 Max: 58.93
Current: 18.68
-230.9
58.93
ROA (%) 6.93
CRL's ROA (%) is ranked higher than
79% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. CRL: 6.93 )
Ranked among companies with meaningful ROA (%) only.
CRL' s 10-Year ROA (%) Range
Min: -21.02  Med: 5.75 Max: 10.68
Current: 6.93
-21.02
10.68
ROC (Joel Greenblatt) (%) 20.40
CRL's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. CRL: 20.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -50.32  Med: 32.13 Max: 84.7
Current: 20.4
-50.32
84.7
Revenue Growth (3Y)(%) 7.00
CRL's Revenue Growth (3Y)(%) is ranked higher than
56% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. CRL: 7.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CRL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -17.6  Med: 6.75 Max: 13.4
Current: 7
-17.6
13.4
EBITDA Growth (3Y)(%) 5.80
CRL's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. CRL: 5.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -18.2  Med: 6.90 Max: 25.1
Current: 5.8
-18.2
25.1
EPS Growth (3Y)(%) 6.40
CRL's EPS Growth (3Y)(%) is ranked higher than
57% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. CRL: 6.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRL' s 10-Year EPS Growth (3Y)(%) Range
Min: -29.4  Med: 7.05 Max: 43.1
Current: 6.4
-29.4
43.1
» CRL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CRL Guru Trades in Q2 2014

Joel Greenblatt 11,280 sh (New)
Ken Fisher 371,824 sh (+76.46%)
Robert Olstein 133,000 sh (+64.20%)
Paul Tudor Jones 18,094 sh (+7.95%)
Westport Asset Management 155,000 sh (unchged)
PRIMECAP Management 1,696,800 sh (-0.06%)
John Rogers 1,950,657 sh (-2.92%)
RS Investment Management 615,915 sh (-4.85%)
Pioneer Investments 123,177 sh (-24.83%)
David Dreman 109,870 sh (-27.79%)
Jim Simons 333,109 sh (-58.44%)
» More
Q3 2014

CRL Guru Trades in Q3 2014

Steven Cohen 131,400 sh (New)
Ray Dalio 4,200 sh (New)
Jim Simons 358,809 sh (+7.72%)
John Rogers 1,996,270 sh (+2.34%)
David Dreman 111,247 sh (+1.25%)
Pioneer Investments 221,616 sh (unchged)
Westport Asset Management 155,000 sh (unchged)
Joel Greenblatt Sold Out
PRIMECAP Management 1,692,800 sh (-0.24%)
Ken Fisher 368,208 sh (-0.97%)
RS Investment Management 585,890 sh (-4.87%)
Robert Olstein 121,000 sh (-9.02%)
Paul Tudor Jones 11,800 sh (-34.79%)
» More
Q4 2014

CRL Guru Trades in Q4 2014

Joel Greenblatt 4,028 sh (New)
Ray Dalio 5,200 sh (+23.81%)
Jim Simons 412,609 sh (+14.99%)
Pioneer Investments 243,374 sh (+9.82%)
David Dreman 116,371 sh (+4.61%)
Ken Fisher 383,102 sh (+4.04%)
John Rogers 2,004,055 sh (+0.39%)
Westport Asset Management 155,000 sh (unchged)
John Rogers 2,004,055 sh (unchged)
PRIMECAP Management 1,692,600 sh (-0.01%)
Paul Tudor Jones 8,700 sh (-26.27%)
RS Investment Management 384,195 sh (-34.43%)
Robert Olstein 32,000 sh (-73.55%)
Steven Cohen 25,700 sh (-80.44%)
» More
Q1 2015

CRL Guru Trades in Q1 2015

Jim Simons 829,332 sh (+101.00%)
Paul Tudor Jones 10,122 sh (+16.34%)
Ken Fisher 402,466 sh (+5.05%)
Westport Asset Management 155,000 sh (unchged)
Joel Greenblatt Sold Out
Robert Olstein Sold Out
Steven Cohen Sold Out
PRIMECAP Management 1,622,300 sh (-4.15%)
Ray Dalio 4,700 sh (-9.62%)
John Rogers 1,758,445 sh (-12.26%)
Pioneer Investments 202,095 sh (-16.96%)
David Dreman 56,322 sh (-51.60%)
RS Investment Management 157,265 sh (-59.07%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl Inc - Jul 22, 2014

Preclinical testing firm Charles River Laboratories Intl, Inc. (CRL) dropped –11.30% as mergers and acquisitions ramped up in the health-care sector. Health-care consolidations have been rising, the most prominent being a proposed $100 billion acquisition of Astra-Zeneca by Pfizer Inc. (PFE), and with mergers come the rationalization of research capabilities. The market tends to react swiftly and sharply to such events. We think such reactions are generally overblown, as the effects tend to be more short-term than long-term; as such we think Charles River has become a better bargain lately.

From John Rogers (Trades, Portfolio)' Ariel Fund Second Quarter 2014 Commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl Inc
Preclinical testing firm Charles River Laboratories Intl, Inc. (CRL) dropped –11.30% as mergers and acquisitions ramped up in the health-care sector. Health-care consolidations have been rising, the most prominent being a proposed $100 billion acquisition of Astra-Zeneca by Pfizer Inc. (PFE), and with mergers come the rationalization of research capabilities. The market tends to react swiftly and sharply to such events. We think such reactions are generally overblown, as the effects tend to be more short-term than long-term; as such we think Charles River has become a better bargain lately. Read more...
John Rogers' Ariel Fund Second Quarter 2014 Commentary
Quarter Ended June 30, 2014 Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.43
CRL's P/E(ttm) is ranked higher than
63% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.30 vs. CRL: 26.43 )
Ranked among companies with meaningful P/E(ttm) only.
CRL' s 10-Year P/E(ttm) Range
Min: 8.59  Med: 24.99 Max: 95.93
Current: 26.43
8.59
95.93
Forward P/E 17.57
CRL's Forward P/E is ranked higher than
63% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.69 vs. CRL: 17.57 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.90
CRL's PE(NRI) is ranked higher than
66% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.40 vs. CRL: 25.90 )
Ranked among companies with meaningful PE(NRI) only.
CRL' s 10-Year PE(NRI) Range
Min: 8.48  Med: 24.62 Max: 77.86
Current: 25.9
8.48
77.86
P/B 5.00
CRL's P/B is ranked lower than
66% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. CRL: 5.00 )
Ranked among companies with meaningful P/B only.
CRL' s 10-Year P/B Range
Min: 0.75  Med: 2.23 Max: 6
Current: 5
0.75
6
P/S 2.54
CRL's P/S is ranked higher than
55% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. CRL: 2.54 )
Ranked among companies with meaningful P/S only.
CRL' s 10-Year P/S Range
Min: 1.12  Med: 2.25 Max: 3.91
Current: 2.54
1.12
3.91
PFCF 18.61
CRL's PFCF is ranked higher than
77% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.29 vs. CRL: 18.61 )
Ranked among companies with meaningful PFCF only.
CRL' s 10-Year PFCF Range
Min: 8.48  Med: 18.03 Max: 907.57
Current: 18.61
8.48
907.57
POCF 14.15
CRL's POCF is ranked higher than
76% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.37 vs. CRL: 14.15 )
Ranked among companies with meaningful POCF only.
CRL' s 10-Year POCF Range
Min: 4.83  Med: 13.19 Max: 19.81
Current: 14.15
4.83
19.81
EV-to-EBIT 21.74
CRL's EV-to-EBIT is ranked higher than
50% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. CRL: 21.74 )
Ranked among companies with meaningful EV-to-EBIT only.
CRL' s 10-Year EV-to-EBIT Range
Min: -10.7  Med: 18.50 Max: 72.4
Current: 21.74
-10.7
72.4
Shiller P/E 77.53
CRL's Shiller P/E is ranked lower than
85% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.22 vs. CRL: 77.53 )
Ranked among companies with meaningful Shiller P/E only.
CRL' s 10-Year Shiller P/E Range
Min: 13.49  Med: 42.71 Max: 93.42
Current: 77.53
13.49
93.42
Current Ratio 2.27
CRL's Current Ratio is ranked lower than
57% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. CRL: 2.27 )
Ranked among companies with meaningful Current Ratio only.
CRL' s 10-Year Current Ratio Range
Min: 1.21  Med: 2.05 Max: 3.49
Current: 2.27
1.21
3.49
Quick Ratio 1.95
CRL's Quick Ratio is ranked lower than
56% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. CRL: 1.95 )
Ranked among companies with meaningful Quick Ratio only.
CRL' s 10-Year Quick Ratio Range
Min: 0.95  Med: 1.73 Max: 3.02
Current: 1.95
0.95
3.02
Days Inventory 39.51
CRL's Days Inventory is ranked higher than
67% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.37 vs. CRL: 39.51 )
Ranked among companies with meaningful Days Inventory only.
CRL' s 10-Year Days Inventory Range
Min: 38.41  Med: 44.87 Max: 76.2
Current: 39.51
38.41
76.2
Days Sales Outstanding 73.47
CRL's Days Sales Outstanding is ranked lower than
61% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.73 vs. CRL: 73.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRL' s 10-Year Days Sales Outstanding Range
Min: 53.42  Med: 61.30 Max: 101.7
Current: 73.47
53.42
101.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.31
CRL's Price/Tangible Book is ranked lower than
89% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.96 vs. CRL: 18.31 )
Ranked among companies with meaningful Price/Tangible Book only.
CRL' s 10-Year Price/Tangible Book Range
Min: 2.86  Med: 7.01 Max: 40.21
Current: 18.31
2.86
40.21
Price/Projected FCF 1.49
CRL's Price/Projected FCF is ranked higher than
71% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.98 vs. CRL: 1.49 )
Ranked among companies with meaningful Price/Projected FCF only.
CRL' s 10-Year Price/Projected FCF Range
Min: 0.94  Med: 1.27 Max: 1.78
Current: 1.49
0.94
1.78
Price/Median PS Value 1.12
CRL's Price/Median PS Value is ranked lower than
52% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. CRL: 1.12 )
Ranked among companies with meaningful Price/Median PS Value only.
CRL' s 10-Year Price/Median PS Value Range
Min: 0.55  Med: 1.23 Max: 1.84
Current: 1.12
0.55
1.84
Price/Peter Lynch Fair Value 3.87
CRL's Price/Peter Lynch Fair Value is ranked lower than
844% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.98 vs. CRL: 3.87 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CRL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.25  Med: 2.40 Max: 3.12
Current: 3.87
1.25
3.12
Price/Graham Number 4.58
CRL's Price/Graham Number is ranked lower than
78% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. CRL: 4.58 )
Ranked among companies with meaningful Price/Graham Number only.
CRL' s 10-Year Price/Graham Number Range
Min: 1.66  Med: 2.94 Max: 8.23
Current: 4.58
1.66
8.23
Earnings Yield (Greenblatt) (%) 4.56
CRL's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.50 vs. CRL: 4.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.4  Med: 5.10 Max: 13.7
Current: 4.56
1.4
13.7
Forward Rate of Return (Yacktman) (%) 8.91
CRL's Forward Rate of Return (Yacktman) (%) is ranked lower than
54% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.24 vs. CRL: 8.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CRL' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 2.8  Med: 5.70 Max: 22
Current: 8.91
2.8
22

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RV6.Germany,
Charles River Laboratories International Inc was incorporated in 1994 in Delaware and in 2000 it completed its initial public offering. Its portfolio includes research models and services required to enablein vivo drug discovery and development. Discovery represents the earliest stages of research in the life sciences, directed at the identification, screening and selection of a lead compound for future drug development. Discovery activities typically extend anywhere from 4-6 years in conventional pharmaceutical research and development timelines. Development activities, which follow, and which can take up to 7-10 years, are directed at demonstrating the safety, tolerability and clinical efficacy of the selected drug candidates. During the preclinical stage of the development process, a drug candidate is tested in vitro (typically on a cellular or sub-cellular level in a test tube or multi-well petri plate) and in vivo (in research models) to support planned or on-going human trials. The Company operates in two segments, namely Research Models and Services (RMS) and Preclinical Services (PCS). Through its RMS segment, the Company supplies research models to the drug development industry. It also provides a variety of related services that are designed to assist its clients in supporting the use of research models in drug discovery and development. With multiple facilities located on three continents (North America, Europe and Asia), it maintains production centers, including barrier rooms and/or isolator facilities. Its PCS business segment provides services that enable its clients to outsource their critical, regulatory-required safety assessment and related drug development activities to the Company. Its RMS segment is comprised of Research Models, Research Model Services and Endotoxin and Microbial Detection. Its Research Models business is comprised of the production and sale of research models and avian vaccine services. Research Model Services also offers a variety of services designed to support its clients' use of research models in screening drug candidates. Its Endotoxin and Microbial Detection business provides non-animal, or in vitro, methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. The Company currently offers preclinical services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Company's customers include global biopharmaceutical companies, small and mid-sized pharmaceutical companies and biotechnology companies, and academic and government institutions. The Company competes in the marketplace on the basis of therapeutic and scientific expertise in in vivo biology, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The Company's business operates in a num
» More Articles for CRL

Headlines

Articles On GuruFocus.com
Carl Appoints Rick Sanderson to the Board of Directors Jun 30 2015 
Weekly Highlight of CEO Sells Oct 13 2014 
John Rogers Comments on Charles River Laboratories Intl Inc Jul 22 2014 
John Rogers' Ariel Fund Second Quarter 2014 Commentary Jul 22 2014 
Robert Olstein’s Largest New Stock Picks Feb 12 2013 
Weekly CFO Sells HIGHLIGHT: TMO, BLOX, VRSK, CRL, INGR, GWRE Jan 13 2013 
Ariel Funds Top Buys: "We think like Halvorsen: CRL is a buy" Jan 11 2012 
Stocks I Can Buy Much Cheaper Than Halvorsen Did Jan 11 2012 
Ken Heebner Top Holdings: AAPL Is a Buy at $380 Jan 11 2012 
Charles River Laboratories International Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Carl Subsidary Signs Data Services Agreement With RA Revenue Automation Jun 18 2015
Analyst Offers Top US Growth Stock Calls for This Week Jun 02 2015
Charles River Laboratories to Present at Jefferies Conference Jun 01 2015
Charles River Laboratories to Present at Jefferies Conference Jun 01 2015
Carl Appoints Industry Expert Bryan Segal to the Board of Directors May 26 2015
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Submission of Matters to a Vote of... May 11 2015
10-Q for Charles River Laboratories International, Inc. May 04 2015
Charles River Laboratories to Present at Baird and Deutsche Bank Conferences May 04 2015
Charles River Laboratories to Present at Baird and Deutsche Bank Conferences May 04 2015
Charles River upgraded by Sun Trust Rbsn Humphrey May 04 2015
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial... Apr 30 2015
Charles River Laboratories Announces First-Quarter 2015 Results from Continuing Operations Apr 29 2015
Charles River misses Street 1Q forecasts Apr 29 2015
Charles River misses Street 1Q forecasts Apr 29 2015
Charles River Laboratories Announces First-Quarter 2015 Results from Continuing Operations Apr 29 2015
Q1 2015 Charles River Laboratories International Inc Earnings Release - After Market Close Apr 29 2015
Charles River Laboratories Int'l, Inc. -- Moody's affirms Charles River's Ba2 CFR; changes outlook... Apr 27 2015
Jefferies Previews Booming Biotech Earnings Apr 27 2015
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Creation of a Direct Financial... Apr 22 2015
Carl Enters Into Letter of Intent for the Purchase of FlowWorks Inc. Apr 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK